Purpose. The analytical performance of the cobas 6800 HIV-1, HBV and HCV assays was verified and evaluated to the COBAS Ampliprep/COBAS TaqMan assays.
INTRODUCTION
Viral load (VL) quantification for human immunodeficiency virus type 1, hepatitis B virus and hepatitis C virus (HIV-1 RNA, HBV DNA and HCV RNA) is performed routinely in clinical diagnostic laboratories in the UK [1, 2] . The rational for VL testing is to establish whether active infection is ongoing, guide clinical management, assess viral response to antiviral therapy during treatment, monitor the potential development of antiviral resistance and disease progression and to confirm adherence [3] [4] [5] [6] [7] . For HIV, the goal of antiviral therapy is to achieve an undetectable VL, generally accepted to be <50 copies ml À1 (cp ml À1 ) [3, 4] .
Clinically defined VL cut-offs have been established for HBV and HCV to guide the initiation of antiviral treatment and prophylaxis, e.g. HBV DNA greater than 2000 IU ml
À1
in chronic hepatitis B and HCV RNA greater than 800 000 IU ml À1 for genotypes 1a and 4 using elbasvirgrazoprevir [8, 9] . The goal of HBV and HCV therapy is to eradicate infection or maintain virological suppression and improve the quality of life and survival by preventing disease progression. The ideal endpoint of HBV and HCV therapy is to reach and maintain an undetectable VL assessed using a molecular method with a sensitivity of <15 IU ml À1 [6, 7] .
Real-time nucleic acid amplification tests are accepted as the gold standard for VL measurement, primarily due to increased sensitivity, improved precision and a broader dynamic range. In June 2015, Roche Diagnostics Ltd released the FDA-approved, CE-IVD-labelled cobas 6800 PCR system and assays. The new instrument and assays were developed to improve turnaround times, efficiencies, traceability and analytical performance [10] . Of note, the new low volume (200 µl) protocol was introduced for the testing of low volume samples, such as paediatrics and hard to bleed patients, and offers the opportunity to repeat viral load testing on the sample when required. In the UK, as in most other countries, diagnostic equipment and assay verification, validation and/or evaluation is mandatory before introduction into clinical use and needs to meet the quality standards of the United Kingdom Accreditation Service British Standard ISO 15189 : 2012 [11] . Currently, there is limited published evidence on the performance of the cobas 6800 system and assays [12] [13] [14] [15] . This has made the verification and evaluation of the equipment and assays challenging. In addition to demonstrating fitness for intended purpose, information on equipment and assay performance is essential to guide laboratory and clinical professionals in VL result interpretation and patient management. The aim of this study was to verify the performance characteristics of the commercial CE-IVD-labelled cobas HIV-1, HBV and HCV assays used on the cobas 6800 instrument and evaluate them against the CAP/CTM system and HIV-1, HBV and HCV Quantitative version 2 assays. 
METHODS

Viral load assays
and unknown (n=32) and HCV genotypes 1a (n=7), 1b (n=4), 1a/b (n=1), 3a (n=7), 4a (n=2) and unknown (n=9).
Residual samples were stored at À80 C. The HIV-1 subtype was assigned from reverse transcriptase and protease sequences using validated routine genotypic resistance assays (TRUGENE HIV-1 and Molecular Diagnostic Unit, Imperial College London, St Mary's Hospital) and Stanford University HIV Drug Resistance Database HIVdb programme. The HCV genotype was determined by NS5B region sequence analysis at the Virus Reference Department, Public Health England. A panel of samples that spanned the dynamic range of each assay was prepared by serial dilution using HIV-1 RNA, HBV DNA and HCV RNA negative human plasma kindly provided by Dr Rice P. S. (Norfolk and Norwich NHS Hospitals NHS Foundation Trust). Five replicates of each concentration were retrieved and tested on each day over five non-consecutive days by several different technicians. The process was repeated for the 200 µl testing protocol using positive residual clinical samples (stored at À80 C) collected between July 2016 and Jan 2017 representing various HIV-1 subtypes A (n=1), B (n=9), C (n=4), D (n=3), G (n=2), CRF02_AG (n=1), CRF01_AE (n=1) and unknown (n=5) and HCV genotypes 1 (n=1), 1a (n=8), 1b (n=1), 1a/b (n=1), 2b (n=1), 3a (n=7) and unknown (n=2).
Limit of detection (LoD), limit of quantification (LoQ) and linearity The LoD, LoQ and linearity of each of the targets were verified using the precision study data. The LoD is the lowest dilution with !95 % of the replicates detecting the target. The LoQ is the lowest dilution with !95 % of the replicates detected and quantified by the cobas 6800.
Analytical specificity
Fifty-five HIV-1 RNA, HBV DNA and HCV RNA Basematrix negative human plasma were tested using the 500 µl testing protocol for each of the targets over three nonconsecutive days. Two daily maintenance, four weekly maintenance, two periodic maintenance, two pipetter tightness check and four equipment rebooting procedures were performed during the period. For HIV-1 assay, samples were tested by three technicians using three reagent lots. For HBV assay, samples were tested by two technicians using two reagent lots. For HCV assay, samples were tested by two technicians using one reagent lot (two different cassettes). 
HIV-1 analytical reactivity
Accuracy
The accuracy of the assays was verified with Quality Control for Molecular Diagnostics 2014 EQA plasma panels (Qnostics, Glasgow, UK). Samples were tested according to the manufacturer's instruction using the 500 and 200 µl protocols.
Evaluation of the cobas 6800 and CAP/CTM HIV-1, HBV and HCV assays
Study population
The evaluation was performed prospectively with clinical samples (see Tables S1 and S2 , available in the online version of this article, for patient demographics) submitted between April and June 2016 from various locations served by three acute tertiary referral NHS hospitals in London (Croydon Health Services NHS Trust, CHS; Kingston Hospital NHS Foundation Trust, KH and St George's University Hospitals NHS Foundation Trust, SGUH). Samples of EDTA blood were routinely collected from patients with chronic HIV-1, HBV and HCV attending specialist outpatient clinics for antiviral treatment and disease monitoring. Samples were included in the study if a minimum of 3 ml of plasma was recovered from the primary blood tube during the study period. A total of 224, 63 and 52 prospective clinical samples were tested in parallel on both cobas 6800 and CAP/CTM for HIV-1, HBV and HCV respectively. Samples were stored at 2-8 C upon receipt and tested within 24 h of venepuncture. Samples were tested on both cobas 6800 and CAP/CTM instruments with alternate loading sequence on each day, and with a delay in loading on either instrument of not more than 4 h, by three technicians. Samples were centrifuged at 2500 g for 10 min before being loaded directly onto the cobas 6800 instrument or aliquoted into sample tubes for loading onto the CAP/CTM. The study was supplemented with pooled clinical plasma samples at various concentrations prepared by serial dilution using the stock plasma samples prepared for the precision study.
Genotype detection and quantification HIV-1 subtype and HBV and HCV genotypes as well as the quantitation values of the prospectively tested clinical samples were used to verify the manufacturer's claim on the subtype and genotype detection.
Statistical analysis
Values were log 10 -transformed before analysis using Microsoft Excel 2010. The agreement between the cobas 6800 and CAP/CTM assays was assessed by the kappa coefficient (GraphPad QuickCalcs). The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were also determined. Pearson correlation coefficient (R) was used to represent the strength and degree of correlation between the assays. The comparability between the assays was also evaluated by the Bland-Altman difference plot and analysis.
RESULTS
Performance of the cobas HIV-1, HBV and HCV assays and cobas 6800 instrument Precision The precision data (Tables S3-S8) were obtained by simulating operational variations that mimicked the VL measurement procedure in routine diagnostic laboratories. For the 500 µl protocol, quantity values were obtained for all replicates for dilutions !60 cp ml À1 for HIV-1, !40 IU ml À1 for HBV and !30 IU ml À1 for HCV. There were satisfactory intraand inter-batch precisions for all assays; the CV of intra-and inter-batch for dilutions !2 log 10 cp ml À1 or IU ml À1 were <10 % and the CV of intra-and inter-batch for dilutions <2 log 10 cp ml À1 or IU ml
À1
, when quantifiable, were <15 %. For the 200 µl protocol, quantity values were obtained for all replicates for dilutions >60 cp ml À1 for HIV-1, !25 IU ml À1 for HBV and >60 IU ml À1 for HCV. There were satisfactory intraand inter-batch precisions for all assays; the CV of intra-and inter-batch for dilutions !2 log 10 cp ml À1 or IU ml À1 were 10 % and the CV of intra-and inter-batch for dilutions <2 log 10 cp ml À1 or IU ml
, when quantifiable, were 15 %.
LoD, LoQ and linearity
Using the precision data (Tables S3-S8) , the LoDs at 500 µl protocol are 20 cp ml À1 , 10 and 15 IU ml À1 for HIV-1, HBV and HCV assay respectively as 25/25 (100 %) replicates were detected. The LoQs are 40 cp ml À1 , 20 and 30 IU ml À1 for HIV-1, HBV and HCV assay respectively as at least 24/25 (96 %) replicates were quantified.
The linearity (R 2 ) of each of the assays was 0.96, 0.97 and 1.00 for HIV-1, HBV and HCV respectively. If dilutions with unquantifiable viral load were removed from analysis, the linearity of HIV-1 and HBV would improve to 1.00. For the 200 µl protocol, the LoDs and LoQs are 50 and 100 cp ml À1 for HIV-1, 20 and 25 IU ml À1 for HBV, and 40 and 80 IU ml À1 for HCV respectively. The R 2 of each of the assays was 0.98, 1.00 and 0.99 for HIV-1, HBV and HCV respectively (unquantifiable viral loads removed from analysis).
Analytical specificity
All negative human plasma samples tested negative. The analytical specificity of the assays was 100 % (95 % CI 93.51 to 100).
HIV-1 analytical reactivity
The HIV-1 assay could detect all the HIV-1 groups, subtypes and CRF's (Table S9 ) with a mean difference of <0.2 log 10 .
Accuracy
Cobas HIV-1, HBV and HCV assays were fully concordant with expected core EQA results using both the 500 and 200 µl protocols (Table S10) . Sample 3 (S3) of HIV-1 target was not detected on initial testing with the 200 µl protocol but became detected at 11 100 cp ml À1 (4.05 log 10 ) on repeat. One educational HIV-1 sample (S2) was not detected by both protocols.
Evaluation of the cobas 6800 and CAP/CTM HIV-1, HBV and HCV assays Correlation and agreement between the cobas 6800 and CAP/CTM assays There were excellent kappa agreement and strong positive correlation between the cobas 6800 and CAP/CTM assays for each of the targets (Table 1 ). There was only one discordant HIV-1 result between the cobas 6800 and CAP/CTM. The sensitivity, specificity, PPV and NPV for all assays were !99 %. The cobas HIV-1 and cobas HCV quantified higher VL than the CAP/CTM with a mean bias of 0.03 log 10 cp ml À1 and 0.17 log 10 IU ml À1 respectively (Figs 1 and 3 ). The cobas HBV assay under quantified HBV DNA with a mean bias of 0.17 log 10 IU ml À1 (Fig. 2) .
Genotype detection and quantification Disagreement in subtype/genotype detection between the assays was not observed. The mean log 10 difference of each HIV-1 subtype and HCV genotype tested that were positive and within the linear range of both assays was <0.30 log 10 (Tables S11-S12 ).
DISCUSSION
HIV-1, HBV and HCV viral load assays are routinely performed for antiviral management and disease monitoring, and clinical laboratories are required to have sensitive and specific assays that demonstrate good performance in precision, accuracy, reliability, operability and turnaround time.
Fully automated assays that require minimal sample and equipment handling are now available of which the Roche cobas 6800 is an example, but a drawback of some commercial systems is the requirement for relatively large amounts of primary sample to accurately and reliably detect low levels of viraemia. We have demonstrated in our studies that the cobas 6800 system can provide reliable and accurate HIV-1, HBV and HCV viral load results with the standard 500 µl and low volume 200 µl protocols that will allow samples to be tested without dilution. The cobas assays can replace CAP/CTM without loss of sensitivity or specificity.
There was excellent agreement and correlation between the cobas 6800 and CAP/CTM assays across a range of patient groups. The difference between the assays on both systems was small and not deemed clinically significant. Similar findings have also been reported by Roche and other laboratories [12] [13] [14] [15] . We have observed an increase in the number of cases of low level HIV-1 viraemia (<200 cp ml
À1
), most likely be due to the ultra-sensitive cobas HIV-1 assay, same day testing on the cobas 6800 compared to batch testing on the CAP/CTM, and an improvement in transport, storage and processing workflows that reduced the likelihood of nucleic acid degradation.
Under-quantification and/or over-quantification associated with particular HIV-1 subtypes and HCV genotypes in Roche assays have been reported in recent years [16] [17] [18] , Positive predictive value 100.00 100.00 100.00
Negative predictive value 98.73 100.00 100.00
Parallel testing was performed by three technicians.
*Due to under-aspiration of sample by the cobas 6800 using the first generation liquid handling software. and these limitations were subsequently rectified by the manufacturer [19, 20] . In the current study, although with relatively small sample numbers, we did not see unexpected quantitation variation between the cobas 6800 and CAP/ CTM assays across different HIV-1 subtypes and HCV genotypes.
The cobas assays performed well in the EQA panels, with <0.3 log 10 difference between the assays and the consensus for the core samples. One educational HIV-1 sample (S2, 121 cp ml À1 ) was not detected by both protocols, possibly due to RNA degradation in storage (2 years at À80 C). Sample 3 (S3) of HIV-1 target was not detected on initial testing with the 200 µl protocol; this could be due to the presence of bubbles, foam, fibrin clots or liquid films on or above the liquid surface, or potential under-aspiration with sample input volume (that is less than 450 µl) using the 200 µl testing protocol [21] . It is therefore prudent to ensure good sample preparation and reagent handling techniques to prevent the formation of foam and bubbles in samples, reagents and controls. To circumvent the above issues, Roche has released the second generation liquid handling software and we have not encountered the above issues following local equipment verification and since the software upgrade in Sept 2016. In addition, since the assay implementation into routine use in June 2016, the cobas assays have so far performed satisfactorily in the UK National External Quality Assessment Service distributions. This has shown that the cobas 6800 equipment and assays are performing well against other comparable molecular assays commonly used.
There was satisfactory intra-and inter-batch precision for all dilutions using either protocol for each of the targets. Poor precisions at low VLs were expected because measuring VL near the LoD and LoQ is inherently prone to PCR stochastic effect at low template concentration and random error in sample preparation and pre-analytic processing. Laboratory staff and clinicians should take into account the intrinsic variations within and between assay runs and the uncertainties of measurement that they have derived in their own laboratory at these lower limits of detection. However, the precision, LoDs, LoQs, linearity and specificity for all targets using either protocol were in agreement with Roche's published performance specification, and thus verified in our hands. The HIV-1 assay detected additional subtypes/ CRFs that were not covered by the manufacturer at validation.
Based on our experience, the cobas 6800 instrument outperformed CAP/CTM in terms of sample throughput, processing volumes, batch sizes and operator hands-on time. The manual sample preparation and test ordering steps have been replaced by direct sampling from primary sample tubes, including low volume samples (<500 µl plasma), and bi-directional interfacing between the cobas 6800 system and the laboratory information management system. By removing the sample preparation step, the risk of aliquoting error and delay in sample testing is eliminated. As the HIV-1 and HCV requests can be combined in one PCR plate, separate batch processing is avoided. Both of these have significantly improved turnaround time while maximizing the use of consumables and cost saving. Unlike the CAP/CTM, the cobas 6800 reagents are kept chilled on board, and this removes the need to removing reagents in the evening and at the weekend. This has prevented the loss of expensive reagents and potential contamination. The onboard fridge has capacity for 12 reagent cassettes, and this allows continuous sample loading in any 8 h shift.
There are limitations in this study. Firstly, HIV-2 cross-reactivity was not thoroughly investigated. Although cross-reactivity was not detected for the HIV-2 WHO international standard and two clinical samples (data not shown), more data are required to provide further assurance. Secondly, HBV genotypes were not investigated as HBV genotyping is not routinely requested for patient management. Nonetheless, the accuracy and evaluation data in this study provide limited information on the HBV genotypes that the assay could detect.
In conclusion, the cobas 6800 equipment and assay performance characteristics have been verified in this study. The equipment and assays showed excellent technical performance with the 500 and 200 µl protocols, and correlated well with the CAP/CTM version 2 assays. The cobas 6800 assays were found to be fit for routine diagnostic investigation and viral load monitoring. The new low volume protocol is ideal for testing low volume clinical samples that would otherwise be rejected.
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